Injection site reactions (e.g. pain, erythema, swelling, itching, burning sensation) occurred at a rate of 8% in subjects treated with Nucala compared with 3% in subjects treated with placebo. USE IN ...
LONDON--(BUSINESS WIRE)-- GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old ...
Third US indication for Nucala demonstrates GSK’s commitment to finding new ways to help patients with eosinophil-driven diseases Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said: ...
RESEARCH TRIANGLE PARK, N.C., Dec. 2, 2015 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Nucala® (mepolizumab), the first and only biologic add-on therapy for people 12 ...
The product is available in 100mg single-dose vials for reconstitution and in 100mg/mL single-dose prefilled autoinjectors and glass syringes. The Food and Drug Administration (FDA) has approved ...
EGPA (formerly known as Churg-Strauss syndrome) is a condition characterized by asthma, high levels of eosinophils (a type of white blood cell that helps fight infection), and inflammation of small- ...
In its heated severe asthma fight with AstraZeneca’s Fasenra, GlaxoSmithKline could take solace in the fact that its drug was more convenient for patients, with a self-administered injection option.
Nucala (100mg dose subcutaneous injection) was first approved in 2015 as an add-on maintenance treatment for patients with severe eosinophilic asthma aged 12 years and older. This approval (40mg dose ...
Nucala, administered by a healthcare professional as a 100mg fixed dose subcutaneous injection every 28 days, is offered to healthcare providers through a network of GSK-authorized wholesalers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results